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Melanin concentrating hormone (MCH) is a regulator of ingestive behavior, but several issues regarding its effects on specific
components of ingestive behavior remain to be elucidated. Therefore, we injected, in the 3rd ventricle of male Wistar rats, saline, MCH
(5 Ag), MCH (5 Ag) together with a MCH1-R antagonist (A, 10 Ag) and the antagonist alone (A, 10 Ag). Our results show that (1)
central administration of MCH stimulates food intake (lab chow and medium high fat diet) and this can be blocked by a MCH1-R
antagonist; (2) the MCH-induced increase in food intake is mediated through increased meal number, meal duration and meal size; (3)
the MCH1-R antagonist is able to significantly reduce the intake of a highly palatable food (condensed sweet milk) and is more
effective in blocking MCH-induced food intake when rats are fed a palatable medium high fat food; and (4) MCH stimulated water
intake independently from and disproportionately to food intake. In conclusion, our results point to an involvement of endogenous
MCH in the enhanced intake of palatable food. Furthermore, they confirm that MCH stimulates not only food intake but also water
intake.
D 2005 Elsevier B.V. All rights reserved.Theme: Neural basis of behavior
Topic: Ingestive behaviors
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The melanin concentrating hormone (MCH), first iso-
lated from salmon pituitaries and implicated in the
regulation of melanin pigment aggregation in the melano-
cytes, has now clearly been established as a neuropeptide
involved in the control of food intake and energy meta-
bolism [19,24]. Central administration of MCH stimulates
food intake [10,20] and chronic i3vt infusion of MCH leads
to hyperphagia and obesity [15]. Mice lacking MCH are
hypophagic and lean [25].0006-8993/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.brainres.2005.09.005
* Corresponding author. Fax: +31 50 363 2331.
E-mail address: a.j.w.scheurink@rug.nl (A.J.W. Scheurink).Two MCH receptor subtypes have been identified,
the MCH1 receptor (MCH1-R, originally named SLC-1)
and the MCH2-R, but only the MCH1-R is found in
rodents [6,21,28]. The MCH1-R is expressed in numer-
ous areas of the brain [3], and mediates the orexigenic
actions of MCH in rodents. MCH1-R knock out mice
are lean, hyperphagic, hyperactive, have an increased
metabolism and are resistant to diet induced obesity (DIO)
[7,17].
In the recent years, several MCH1-R antagonists such as
T-226296 [27], SNAP-7941 [4] or the antagonist charac-
terized by Bednarek et al. [1], Shearman et al. [23] and
Mashiko et al. [18] have been developed. These drugs
significantly reduce MCH-induced increase in food intake
when MCH is injected centrally and the antagonist is given(2005) 32 – 38
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or intracerebroventrically [18,23].
Several questions addressing the role of MCH in
ingestive behavior remain to be answered. First, there is
controversy regarding the effect of MCH on water intake.
Shearman et al. [23] showed that MCH influences food
intake without affecting water intake while Clegg et al. [9]
demonstrated that central injections of MCH into the third
ventricle stimulated both food intake and water intake. In
the latter studies, when food was not available, MCH still
stimulated water intake.
The role of endogenous MCH in food intake is also still a
subject of discussion. Chronic treatment with an MCH1-R
antagonist alters appetite, body weight and adiposity in
Sprague–Dawley rats [23] and in diet-induced obese (DIO)
mice [18]. In addition, Borowsky et al. [4] showed that the
MCH1-R antagonist SNAP-7941 injected intraperitoneally
would block the intake a highly palatable food (sweet
condensed milk). However, there are no data available on
an acute effect of MCH1-R antagonists on normal lab chow
intake. Taken together, these data suggest a role for
endogenous MCH in the intake of palatable food, though
Clegg et al. [8] demonstrated that rats injectedMCH centrally
failed to develop a preference for the high (more palatable) or
the low (less palatable) fat diets in a choice paradigm.
The aim of the present experiments was to further
characterize the effects of MCH on food and water intake. In
the first series of experiments, we investigated, in rats given
either lab chow or a medium high fat diet, whether feeding
induced by central administration of MCH could be blocked
by central injections of a MCH1-R antagonist peptide
(corresponding to Compound 30 in Bednarek et al. [1] and
to Compound B in Shearman et al. [23]). In the next series
of experiments, we investigated whether the MCH1-R
antagonist blocked MCH-induced water intake. In the third
series of experiments, we assessed whether central injection
of the MCH1-R antagonist would block the consumption of
a highly palatable food. Finally, we determined how MCH
influences meal size, meal number, meal duration and rate
of ingestion, by analyzing in detail the meal patterns of rats
after injection of MCH and/or the MCH1-R antagonist.2. Materials and methods
2.1. Animals and diets
All methods and experiments were approved by the
Animal Care Committee of the University of Groningen.
Forty-onemaleWistar rats weighing 280–300 g at the start of
the experiments were included in the study. They were ob-
tained from the breeding colony maintained at the University
of Groningen. Animals were allowed 7–10 days to become
habituated to the experimental conditions (individual housing
in rooms with controlled humidity and temperature, 12/12 h
dark/light cycle, lights on from 0.00 to 12.00).After habituation, rats were implanted stereotaxically
with a 22-gauge stainless steel guide cannula (Plastics One,
Roanoke, VA) into the third cerebral ventricle (i3vt) under
O2/N2O-isoflurane anesthesia. FinadyneR (1 g/kg BW,
Schering-Plough, Maarssen, The Netherlands) was given
to reduce surgery stress and the rats were allowed to recover
for 5–7 days. After recovery, correct placement of the
cannula was confirmed by injection of 10 ng of angiostensin
II through an injector placed in the guide cannula. Only the
rats that drank more than 6 ml of water within 30 min after
the injection were used in the subsequent experiments.
Rats were fed regular lab chow (RMH-B, Hope Farms,
Woerden, The Netherlands; 3.8 kcal/g). In Experiment 1b, a
42% fat diet (Medium high fat-MHF-diet, Purified High Fat
diet with lard, 4031.09, Arie Block BV, Woerden, The
Netherlands; 4.7 kcal/g) was also used.
2.2. Chemicals
MCH was purchased from Bachem (Weil am Rhein,
Germany). The MCH1-R antagonist peptide was synthe-
sized at Bachem (Weil am Rhein, Germany) and it consists
of the amino acid sequence Acetyl-Arg-Cys-Met-5-amino-
pentanoyl-Arg-Val-Tyr-5-aminopentanoyl-Cys-NH2. This
peptide sequence has previously been characterized in vitro
and in vivo by Bednarek et al. ([1], ‘‘Compound 30’’),
Shearman et al. ([23]; ‘‘Compound B’’) and Mashiko et al.
[18]. The antagonist peptide was shown to exhibit a high
affinity for the MCH1-R with a Ki value of 9.9 nM. It
showed an antagonistic activity in a functional assay with an
IC50 value of 15 nM [18].
2.3. Experiments
2.3.1. Experiment 1: effects of i3vt administration of MCH
and the MCH1-R antagonist (A) on food intake
Rats were injected with either saline (4 Al), MCH (5 Ag
in 4 Al saline), MCH and the MCH1-R antagonist (5 Ag + 10
Ag, respectively, in 4 Al saline) or the MCH1-R antagonist
alone (10 Ag in 4 Al of saline) through an injector ending 1
mm lower than the guide cannula. This dose of antagonist
was chosen because it was shown to be effective by
Shearman et al. [23]. The study was done following a
cross-over design, each rat being submitted to the 4
conditions with a week between each i3vt injection. The
injections were performed 30 min before lights went off.
Food hoppers were weighed at the onset of dark and then 1,
2, 3, 4, 6 and 24 h later.
Two studies were performed in Experiment 1. In experi-
ment 1a, rats were kept on normal lab chow, and in
experiment 1b, the MHF diet was given for the duration of
the experiment. The rats in the second group were allowed
to get accustomed to the MHF diet several times in the week
prior to the experiment. Typically, they were given 1–2
pellets of the MHF diet every day in their cage. Animals
would avidly eat that food.
Fig. 1. Cumulative food intake (kcal) after an acute i3vt injection of saline
(n = 7), MCH (5 Ag, n = 7), MCH (5 Ag) + A (10 Ag) (n = 7) or A (10 Ag, n =
3) in rats fed lab chow. Means T SEM. *, **, ***P < 0.05, 0.01 and 0.001,
MCH vs. saline. #, ##, ###P < 0.05, 0.01 and 0.001, MCH vs. MCH + A.
$, $$, $$$P < 0.05, 0.01 and 0.001, A vs. saline.
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and MCH1-R antagonist (A) on water intake
The same design as described in Experiment 1 was used
in this experiment, except that the experiment was shortened
to 6 h. Rats were allowed ad libitum food and water access
prior to the experiment. Food was removed at the time of the
injection and was returned after 6 h to allow assessment of
water intake independently of food intake.
2.3.3. Experiment 3: meal pattern analysis after i3vt
administration of MCH and MCH1-R antagonist (A)
Rats were injected with saline, MCH, MCH + MCH1-R
antagonist or the MCH1-R antagonist alone 30 min before
the start of the dark phase, following the same procedure as
described in Experiment 1. Each rat was successively
submitted to each condition in a cross-over design, with 7
days between each i3vt injection. Food intake was then
recorded for 24 h using a TSE Drinking and Feeding
Monitor (TSE Systems GmbH, Bad Hamburg, Germany).
Food was weighed at 10 s intervals. Meal number, meal
duration (s), meal size (g) and ingestion rate (g/min) were
then determined. The food intake signal was analyzed as
follows: a meal needed to be larger than 0.1 g and longer
than 10 s and two distinct meals needed to be separated by
an Inter Meal Interval (IMI) of 10 min [2,5,13]. We
evaluated the data using different IMI (between 1 and 10
min) and this did not appreciably change the results (data
not shown).
2.3.4. Experiment 4: sweet condensed milk intake after i3vt
administration of a MCH1-R antagonist in satiated rats
The protocol used in this experiment was adapted from
Borowsky et al. [4]. Four hours after the start of the dark
phase (i.e., at 16.00), food was removed from the rats for 1
h (i.e., from 16.00 to 17.00). Rats were then offered sweet
condensed milk (Friesland Dairy Foods, Leeuwarden, The
Netherlands) for 30 min (i.e., from 17.00 to 17.30).
Finally, food was returned at 17.30. Rats were trained
for 6 days on this paradigm. On the test day (day 7), rats
were injected i3vt with either saline (4 Al) or the MCH1-R
antagonist (A, 10 Ag in 4 Al saline) between 16.30 and
17.00, i.e., 30 min before being given access to the sweet
condensed milk. This timing was chosen since it was
effective in Experiments 1–3. The sweet condensed milk
intake was assessed and expressed as a percentage of the
average intake calculated over the 3 last days of the
training period.
2.4. Statistics
Results are presented as means T SEM. All statistical
analyzes were performed using SPSS 12.0.1 (Chicago, IL).
A paired-samples t test was used to test the significance
(P < 0.05) of the differences between the different
injections (MCH vs. saline, MCH vs. MCH + A, and A
vs. saline, respectively). An ANOVA with repeated mea-sures was used to test the effect of the treatments (saline,
MCH, MCH + A or A) on the 24-h cumulative food intake
in Experiment 3.3. Results
3.1. Experiment 1: effects of MCH and MCH1-R antagonist
(A) on food intake
Intra-cerebroventricular (i3vt) injection of MCH signifi-
cantly increased food intake in rats fed a lab chow diet (Fig. 1,
results expressed in kcal). The orexigenic effect of MCH was
the strongest during the first 3 h of the dark phase. When
compared to the rats injected saline, the increase in food in-
take reached +94% (P < 0.01) at 2 h and +56% (P < 0.05) at
3 h.
The MCH1-R antagonist (A) significantly attenuated the
orexigenic effect of MCH from 2 to 4 h after the start of the
dark phase (41%, 43% and 43% vs. MCH at 2, 3 and 4
h, respectively, P < 0.05). Even at time point 24 h, the
cumulative food intake of the rats given MCH together with
the MCH1-R antagonist was still significantly reduced
compared to the rats given the MCH injection (22% vs.
MCH, P < 0.05). When given alone, the antagonist did not
affect food intake nor body weight when compared to the
control injection.
The same experiment was repeated in rats fed a medium
high fat diet (MHF diet, 42% of energy as fat) (Fig. 2, results
expressed in kcal). MCH injected centrally before lights off
stimulated food intake during the first hour of the dark phase
(+98% and +60% vs. saline at 2 and 3 h, respectively, P <
0.05). The antagonist significantly attenuated the MCH-
induced food intake during the first 6 h of the dark phase
(62%, 61% and 51% vs. MCH at 3, 4 and 6 h,
respectively, P < 0.01). Moreover, when injected alone, the
antagonist significantly reduced food intake compared to the
control condition (39% at 4 h and 20% at 6 h vs. Saline,
P < 0.05).
Fig. 4. Cumulative 24 h food intake (kcal) after an acute i3vt injection of
saline (n = 6), MCH (5 Ag, n = 6), MCH (5 Ag) + A (10 Ag) (n = 7) or A
(10 Ag, n = 6) in rats. Means T SEM. MCH (–?– ), Saline (–>– ), MCH +
A (–4– ) and A (–3–). *, **, ***P < 0.05, 0.01 and 0.001, MCH vs.
saline. #, ##, ###P < 0.05, 0.01 and 0.001, MCH vs. MCH + A. $, $$, $$$P <
0.05, 0.01 and 0.001, A vs. saline. **P < 0.01 A vs. saline.
Fig. 2. Cumulative food intake (kcal) after an acute i3vt injection of saline
(n = 6), MCH (5 Ag, n = 6), MCH (5 Ag) + A (10 Ag) (n = 7) or A (10 Ag, n =
6) in rats fed a 42% fat diet. Means T SEM. *, **, ***P < 0.05, 0.01 and
0.001, MCH vs. saline. #, ##, ###P < 0.05, 0.01 and 0.001, MCH vs. MCH +
A. $, $$, $$$P < 0.05, 0.01 and 0.001, A vs. saline.
C. Morens et al. / Brain Research 1062 (2005) 32–38 353.2. Experiment 2: effects of MCH and MCH1-R antagonist
(A) on water intake
Fig. 3 presents the 6-h cumulative water intake of rats
injected saline, MCH, MCH + A or A alone 30 min before
the start of the dark phase. MCH injected centrally
significantly stimulated water intake from the 1st hour to
6 h after light off (+109%, +131%, +93%, +68% and +49%
vs. saline at 1 (P < 0.01), 2 (P < 0.001), 3 (P < 0.01), 4 (P <
0.01) and 6 (P < 0.05) h, respectively). The MCH1-R
antagonist was able to block MCH-induced water intake
(44% vs. MCH at 2 and 3 h, P < 0.05). Water intake of the
rats injected MCH + Awas not different from that of the rats
given saline injection. When injected alone, the MCH1-R
antagonist had no effect on water intake.
3.3. Experiment 3: effects of MCH and MCH1-R antagonist
(A) on meal pattern
Fig. 4 shows the 24-h cumulative chow intake (expressed
in grams) of rats injected with saline, MCH, MCH + A or A
alone 30 min before the start of the dark phase. There was aFig. 3. Cumulative water intake (ml) after an acute i3vt injection of saline
(n = 12), MCH (5 Ag, n = 12), MCH (5 Ag) + A (10 Ag) (n = 12) or A
(10 Ag, n = 12) in rats. Means T SEM. *, **, ***P < 0.05, 0.01 and
0.001, MCH vs. saline. #, ##, ###P < 0.05, 0.01 and 0.001, MCH vs. MCH +
A. $, $$, $$$P < 0.05, 0.01 and 0.001, A vs. saline.significant overall effect of the treatment (saline, MCH,
MCH + A or A) on the 24-h cumulative food intake curves
(ANOVA with repeated measures, P = 0.005).
Table 1 shows the results of the meal pattern analysis
performed after i3vt injections of saline, MCH, MCH + A or
A alone. The meal pattern analysis was performed over the
first 2 h of the dark phase, and over the entire dark phase
(0–12 h).
During the first 2 h of the dark phase, meals number (P <
0.05 vs. saline), meal duration (P < 0.05 vs. MCH + A),
meal size and ingestion rate were increased in the MCH-
treated rats, all contributing to a significantly higher 2 h
cumulative food intake in those rats (P < 0.05) when
compared to the rats injected saline or MCH + MCH1-R
antagonist. The antagonist injected alone had no effect on
the parameters measured.
Over the entire 12-h dark period, MCH injected i3vt led
to a higher number of meals and a slightly increased meal
duration (but these changes were not statistically significant)
compared to what was observed in the 3 other groups. This
resulted in an increased 12 h cumulative food intake. This
difference, however, was significant only when compared to
the MCH + A-treated rats (P < 0.05).
3.4. Experiment 4: sweet condensed milk intake after an i3vt
injection of MCH1-R antagonist in satiated rats
Rats were very eager to drink the condensed sweet milk,
and ingested in average (calculated on the 3 days prior to the
experiment) 13.3 T 0.6 g within 30 min. Fig. 5 shows the
condensed sweet milk intake of the rats on the 3 training
days before the experiment and the results of the acute i3vt
injection of the MCH1-R antagonist. There was a significant
reduction (P = 0.004) in the sweet condensed milk intake
Table 1
Meal pattern analysis, over the 1st hours of the dark phase and the entire 12 h dark phase
Eating parameter Saline MCH MCH + A A
0–2 h Meal number 2.1 T 0.6a 2.9 T 0.4a 2.1 T 0.4 2.0 T 0.3
Meal duration (s) 361 T 69 422 T 87a 248 T 49a 287 T 56
Meal size (g) 1.9 T 0.3 2.2 T 0.2 1.8 T 0.3 2.3 T 0.4
Ingestion rate (g/min) 0.33 T 0.03 0.53 T 0.21 0.70 T 0.22 0.64 T 0.13
Cumulative FI (g) 5.0 T 1.4a 9.6 T 1.2a,b 5.8 T 0.9b 7.3 T 0.8
0–12 h Meal number 8.3 T 1.1 9.3 T 1.0 7.7 T 1.1 5.7 T 0.4
Meal duration (s) 431 T 59 483 T 58 363 T 42 329 T 41
Meal size (g) 2.1 T 0.2 2.4 T 0.2 2.1 T 0.1 2.9 T 0.5
Ingestion rate (g/min) 0.35 T 0.03 0.45 T 0.13 0.57 T 0.11 0.68 T 0.17
Cumulative FI (g) 16.5 T 1.4 21.2 T 2.0a 15.6 T 1.5a 16.2 T 2.9
Means T SEM. Within a row, values with the same superscript letter are significantly different, P < 0.05.
C. Morens et al. / Brain Research 1062 (2005) 32–3836after the antagonist injection when compared to the i3vt
saline injection.4. Discussion
The experiments described in this paper were designed to
investigate the effects of MCH and a MCH1-R antagonist
on normal and palatable food intake, on meal patterns and
on drinking behavior. The most important finding is that
administration of the MCH1-R antagonist successfully
reduced the intake of a palatable medium high fat diet and
of a highly palatable sweet condensed milk but failed to
inhibit the intake of regular chow. In addition, the MCH1-R
antagonist prevented the MCH-induced increase in food
intake, and this effect was more pronounced when animals
were fed a medium high fat diet. These results support a role
for endogenous MCH in the intake of, particularly, palatable
food. Our results do also confirm that exogenous MCH also
stimulates water intake, independently of food intake and
that this effect can be blocked by a MCH1-R antagonist.
Finally, the meal pattern analysis performed show that both
an increased meal number and meal duration in the MCHFig. 5. (A) 30 min sweet condensed milk intake (g) during the last 3 days of the tra
over the last 3 days of the training period, (C) 30 min sweet condensed milk intake
A (10 Ag, n = 7) and (D) 30 min sweet condensed milk intake (g) on the experimen
of the average intake calculated over the 3 previous training days) in rats. Meansadministered rats participated in the increased food intake
observed.
The results of Experiment 1 show that exogenous MCH
administered in the 3rd ventricle is able to stimulate food
intake in rats on normal lab chow or a medium high fat diet.
Two hours after lights off, food intake in the rats injected
with MCH was doubled when compared to controls, and it
was still increased by 56–60% at 3 h. This effect could be
blocked by concomitant injection of the MCH1-R antago-
nist. Our results confirm those of, e.g., Rossi et al. [20] or
Della-Zuana et al. [11], and further support the role of MCH
as an orexigenic peptide involved in the central control of
food intake, as well as a role for the MCH1-R in mediating
the effects of MCH on food intake.
When injected alone, the MCH1-R antagonist did not
affect food intake in the rats fed lab chow (Experiment 1a).
In contrast, it induced a significant reduction in food intake
at 4 (39%) and 6 (20%) h in the rats given the MHF diet
(Experiment 1b). The antagonist was also more effective in
blocking the MCH-induced increase in food intake in rats on
the MHF diet (50 to 60% compared to saline-injected rats)
than in those on lab chow (40%). The antagonist was also
able to reduce the intake of a highly palatable food (sweetining period, (B) average 30 min sweet condensed milk intake (g) calculated
(g) on the experimental day after an acute i3vt injection of saline (n = 7) or
tal day after an acute i3vt injection of saline or A (expressed as a percentage
T SEM. *P < 0.05 and **P < 0.01 A vs. saline.
C. Morens et al. / Brain Research 1062 (2005) 32–38 37milk test, Experiment 4), confirming the data of Borowsky
et al. [4] (who used a different antagonist).
Taken together, our results are in agreement with the idea
developed by Elliot et al. [12] that MCH might be involved
in enhancing appetite for palatable food, which would be
consistent with an involvement of MCH in the hedonic
reward circuit. Recently, Georgescu et al. [14] showed that
MCH acts in the Nucleus Accumbens (NAc) to modulate
feeding behavior confirming earlier ideas by DiLeone et al.
[11]. The NAc is a major reward region in the brain and
shows enhanced expression of the MCH1-R mRNA [21]. It
has been suggested that the MCH trafficking between the
lateral hypothalamus (LH) and the NAc may play a role in
communicating hedonic and/or rewarding aspects of food
[22]. Several lines of evidence point to an involvement of
the mesolimbic dopamine system in the effects of MCH on
palatable food intake. First, the NAc is part of the
mesolimbic dopamine system, and Smith et al. [26] showed
an increased sensitivity of the mesolimbic dopamine system
in MCH1-R KO mice, which may be indicative of altered
reward mechanism. And second, Georgescu et al. [14]
suggested that MCH could stimulate feeding via an
increased drive to feed, through its interaction with the
NAc dopamine system. And finally, Clegg et al. (personal
communication) were able to block the MCH-induced
hyperphagia with a dopamine antagonist. Taken together,
this suggests that interactions between MCH and the
monoamine systems might participate in the reward-related
effects of MCH.
The results of Experiment 2 show that centrally admin-
istered MCH stimulates water intake independently of food
intake, and that this effect can be blocked by the MCH1-R
antagonist. In our experiment, water intake was also
increased disproportionately to food intake. Three hours
after the start of the dark phase, water intake was increased
by 93% in the rats MCH-administered when compared to the
control condition, when food intake was increased by only
57% and 60% (Experiments 1a and 1b, respectively). Taken
together, those data are in line with a specific role for MCH
in the control of water intake. Our results are in agreement
with those of Clegg et al. [9], but not with those of Shearman
et al. [23] who failed to find any effect of their MCH1-R
agonist and antagonist on water intake. The different
experimental set-ups might explain the disaccording results.
In the present experiment and in the set-up used by Clegg et
al. [9], food was removed during the experiment so that rats
would have access to water only. This effect of MCH on
fluid intake might also explain, in part, the effect of the
MCH1-R antagonist on the intake of the condensed sweet
milk in Experiment 4, since the appetitive diet was given to
the rats in a liquid form. However, we believe that this effect
is less important, based on the observation that the
antagonist does not affect water intake by itself.
Lastly, our meal pattern analysis (Experiment 3) showed
that animals administered MCH i3vt showed increased meal
number (P < 0.05 vs. saline), increased meal duration (P <0.05 vs. MCH + A) and a trend towards increased meal size.
These data demonstrate that multiple parameters related to
ingestive behavior contribute to MCH-induced increase in
food intake, and are in contrast with those of Kowalski et al.
[16] who showed that the MCH1-R antagonist T-226296
reduces food intake when given to DIO rats via a reduction
in meal size but not meal frequency, supporting then a role
for MCH in meal size regulation.
In conclusion, our results obtained with the MCH1-R
antagonist further support an involvement of endogenous
MCH in the enhanced intake of palatable food. More-
over, we confirm that MCH stimulates not only food
intake but also water intake, and this, independently, of
food intake.Acknowledgments
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